148 related articles for article (PubMed ID: 35725639)
1. Evaluation of the safety and efficacy of a Fuling-Zexie decoction for people with asymptomatic hyperuricemia: protocol for a prospective, double-blinded, randomized, placebo-controlled clinical trial.
Yan J; Zhou Y; Yang Q; Wu J; He X
Trials; 2022 Jun; 23(1):517. PubMed ID: 35725639
[TBL] [Abstract][Full Text] [Related]
2. "Yellow-dragon Wonderful-seed Formula" for hyperuricemia in gout patients with dampness-heat pouring downward pattern: a pilot randomized controlled trial.
Yu XN; Wu HY; Deng YP; Zhuang GT; Tan BH; Huang YZ; Tang SY; Tu X; Jordan JB; Zhong S
Trials; 2018 Oct; 19(1):551. PubMed ID: 30314508
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Chinese herbal medicine Jiangniaosuan formula for treatment of hyperuricemia: study protocol for a double-blinded non-inferiority randomized controlled clinical trial.
Guo Y; Lu H; Gan J; Li D; Gao J; Zhang C
Trials; 2022 Jan; 23(1):1. PubMed ID: 34980237
[TBL] [Abstract][Full Text] [Related]
4. Traditional Chinese medicine in the treatment of patients with hyperuricemia: A randomized placebo-controlled double-blinded clinical trial.
Leong PY; Chen HH; Gau SY; Chen CY; Su YC; Wei JC
Int J Rheum Dis; 2024 Jan; 27(1):e14986. PubMed ID: 38014453
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the effectiveness and safety of acupuncture on serum uric acid in asymptomatic hyperuricemia population: a randomized controlled clinical trial study protocol.
Yu LL; Li CN; Fang MY; Ma Y; Wang B; Lin FP; Liu WH; Tu SH; Chen Z; Xie WX; Zhang RY; Huang Y; Zheng CH; Wang Y
Front Endocrinol (Lausanne); 2023; 14():1218546. PubMed ID: 37900149
[TBL] [Abstract][Full Text] [Related]
6. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.
Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):53-61. PubMed ID: 31792640
[TBL] [Abstract][Full Text] [Related]
8. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
[TBL] [Abstract][Full Text] [Related]
9. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
Xu S; Liu X; Ming J; Chen S; Wang Y; Liu X; Liu H; Peng Y; Wang J; Lin J; Ji H; Liu B; Lu Y; Liu P; Zhang Y; Ji Q
Int J Rheum Dis; 2015 Jul; 18(6):669-78. PubMed ID: 26013187
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study.
Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):44-52. PubMed ID: 31754882
[TBL] [Abstract][Full Text] [Related]
11. Comment on serum urate-lowering efficacy and safety of Tigulixostat in gout patients with hyperuricemia: A randomized, double-blind, placebo-controlled, dose-finding trial.
Hsu TM; Chang HW; Chen AL; Wei JC
Int J Rheum Dis; 2024 Jan; 27(1):e15024. PubMed ID: 38287554
[No Abstract] [Full Text] [Related]
12. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.
Hosoya T; Sasaki T; Hashimoto H; Sakamoto R; Ohashi T
J Clin Pharm Ther; 2016 Jun; 41(3):298-305. PubMed ID: 27079434
[TBL] [Abstract][Full Text] [Related]
13. Effects of
Lee S; Han EH; Lee SH; Lim MK; Kim CO; Kang S
J Med Food; 2020 May; 23(5):508-514. PubMed ID: 32150484
[No Abstract] [Full Text] [Related]
14. A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial for Evaluation of the Efficacy and Safety of DKB114 on Reduction of Uric Acid in Serum.
Park YH; Kim DH; Lee JS; Jeong HI; Lee KW; Kang TH
Nutrients; 2020 Dec; 12(12):. PubMed ID: 33322063
[TBL] [Abstract][Full Text] [Related]
15. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R
Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732
[TBL] [Abstract][Full Text] [Related]
17. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).
Wada T; Hosoya T; Honda D; Sakamoto R; Narita K; Sasaki T; Okui D; Kimura K
Clin Exp Nephrol; 2018 Aug; 22(4):860-870. PubMed ID: 29372470
[TBL] [Abstract][Full Text] [Related]
18. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
[TBL] [Abstract][Full Text] [Related]
19. Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
Gunawardhana L; McLean L; Punzi HA; Hunt B; Palmer RN; Whelton A; Feig DI
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29102979
[TBL] [Abstract][Full Text] [Related]
20. Acupuncture for serum uric acid in patients with asymptomatic hyperuricemia: A randomized, double-blind, placebo-controlled trial.
Huang Y; Meng J; Sun B; Xiang T; Zhou X; Xu B; Wu Y; Chen Z; Zhang S
Int J Cardiol; 2017 Apr; 232():227-232. PubMed ID: 28087178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
